Targeted immunohistochemistry showed tumor cell positivity for cytokeratin, nuclear beta-catenin, CD56, dot-like CD99, progesterone receptor (focal), and aberrant focal CD31 expression, with negativity for ERG and other vascular markers, confirming the diagnosis of SPN. This evidence concerns the gene CTNNB1 and neoplasm.